EBITDA Margin % is calculated as EBITDA divided by its Revenue. Microbix Biosystems's EBITDA for the
three
months ended in Mar. 2026 was C$-0.71 Mil. Microbix Biosystems's Revenue for the
three
months ended in Mar. 2026 was C$3.38 Mil. Therefore, Microbix Biosystems's EBITDA margin for the quarter that ended in Mar. 2026 was -21.02%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Microbix Biosystems EBITDA Margin % Related Terms
Microbix Biosystems EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Microbix Biosystems's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSX:MBX vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Microbix Biosystems's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microbix Biosystems EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Microbix Biosystems's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Microbix Biosystems's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microbix Biosystems (TSX:MBX) has a EBITDA Margin % of -21.02% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Microbix Biosystems and its competitors. According to the industry distribution chart, Microbix Biosystems ranks #383 out of 944 companies in the Biotechnology industry, placing it in the top 40.6%.
Is Microbix Biosystems' EBITDA Margin % too high?
Microbix Biosystems' current EBITDA Margin % is -21.02%. Based on the distribution chart, Microbix Biosystems ranks #383 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Microbix Biosystems has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Microbix Biosystems' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Microbix Biosystems ranks #383 out of 944 companies for EBITDA Margin %. This puts Microbix Biosystems in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Microbix Biosystems and its competitors. Microbix Biosystems's current EBITDA Margin % is -21.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbix Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Microbix Biosystems (TSX:MBX) is currently considered Modestly Overvalued. The stock's GF Value™ is C$0.24, compared to a current price of C$0.31 — trading 27.1% above its estimated fair value. The current EBITDA Margin % is -21.02%. Microbix Biosystems' overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Microbix Biosystems (TSX:MBX), the current EBITDA Margin % is -21.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Microbix Biosystems (TSX:MBX) Overvalued in 2026?
Based on GuruFocus' analysis, Microbix Biosystems stock appears to be overvalued.
The current stock price of C$0.31 is trading 27.1% above its estimated GF Value™ of C$0.24.
GuruFocus considers Microbix Biosystems to be Modestly Overvalued.
Key valuation signals for TSX:MBX:
EBITDA Margin %: -21.02%
GF Value™: C$0.24 vs. price of C$0.31 (27.1% above fair value)
No single metric tells the full story. See the TSX:MBX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows, and viral transport medium to enable collection of patient test samples; and the development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.
52GF Score
Get the complete analysis for TSX:MBX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:MBX has been successfully added to your 
